FDA grants Bayer accelerated review for radium-223 dichloride

02/19/2013 | Fox Business · OncLive

The FDA has given priority review status to Bayer's radium-223 dichloride, used to treat prostate cancer. The designation will cut several months from the usual review timeline. The company is seeking approval for use of the drug in patients with castration-resistant prostate cancer that has spread to bone.

View Full Article in:

Fox Business · OncLive

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX